Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626662 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
A Phase 1 study of Cardiovascular Disease, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
- 9
- Study locations
NCT03626662 is a Phase 1 study of Cardiovascular Disease that has completed, run by Amgen. The registered enrollment target is 79 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT03626662, a Phase 1 study of Cardiovascular Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) \[Lp(a)\]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 890
Study Locations (9)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Jacksonville Center for Clinical Research - Jacksonville
- QPS Miami Research Associates - South Miami
California
- Orange County Research Center - Tustin
Kansas
- University of Kansas Medical Center - Kansas City
New York
- New York University - New York
Ohio
- Medpace Inc - Cincinnati
South Australia
- Clinical Medical and Analytical eXellence CMAX - Adelaide
Western Australia
- Linear Clinical Research Limited - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2023-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03626662
The ClinicalTrials.gov registry entry for NCT03626662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (97% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03626662 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT03626662 about?
NCT03626662 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)". This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) \[Lp(a)\]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
What is the current status of trial NCT03626662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2018-07-30. Estimated completion is 2023-04-18.
What conditions does trial NCT03626662 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT03626662?
The interventions under investigation include: Placebo (DRUG), AMG 890 (DRUG).
Who is sponsoring clinical trial NCT03626662?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03626662 being conducted?
This trial has 9 study locations across California, Florida, Kansas, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
RECRUITING · Phase 1
-
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
COMPLETED · Phase 1
-
Fructose-Induced Palmitate Synthesis in Overweight Subjects
COMPLETED · Phase 1
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Single-tracer Multiparametric PET Imaging
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.